Clinical Research Directory
Browse clinical research sites, groups, and studies.
2 clinical studies listed.
Filters:
Tundra lists 2 Acute Respiratory Distress Syndrome, Adult clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07942623
Effect of Adding Sigh Maneuver to Lung Protective Ventilation on Gas Exchange and ARDS Incidence in ARDS High-Risk ICU Patients
Sigh maneuver is a periodic deep breath aimed at reopening collapsed alveoli. This single-center, single-blind randomized controlled trial evaluated whether adding a sigh maneuver to Lung Protective Ventilation (LPV) improves acute gas exchange and reduces the incidence of Acute Respiratory Distress Syndrome (ARDS) compared to LPV alone, in mechanically ventilated adult ICU patients at high risk of ARDS (Lung Injury Prediction Score, LIPS \> 4). Fifty-two patients were randomized 1:1, stratified by baseline PF ratio, to receive either LPV with an added sigh maneuver (intermittent higher-pressure breaths via a Dräger Evita V300 ventilator) or LPV alone for 20 minutes, following a 20-minute standardization phase. The primary outcome was change in PaO2/FiO2 ratio; secondary outcomes included changes in PaO2, dynamic compliance, ventilatory ratio, PaCO2, and the incidence of ARDS (Berlin criteria) over one week of observation.
Gender: All
Ages: 18 Years - 65 Years
Updated: 2026-11-17
1 state
NCT05496868
Add-on Reparixin in Adult Patients With ARDS
Study objectives 1. To characterize the efficacy of reparixin in ameliorating lung injury and systemic inflammation and expediting clinical recovery and liberation from mechanical ventilation in adult patients with moderate to severe ARDS (PaO2/FIO2 ratio ≤ 200). 2. to assess the effect of reparixin on systemic biomarkers linked to a hyper-inflammatory ARDS phenotype. 3. To evaluate the safety of reparixin vs. placebo in patients enrolled in the study.
Gender: All
Ages: 18 Years - Any
Updated: 2026-05-11
28 states